A Study to Evaluate Preventive Treatments for GPRC5D-related Oral Events
Multiple Myeloma
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2
- Patients
- 210 (planned)
- Started
- Aug 26, 2024
- Main results expected
- May 30, 2030
- Fully finished
- May 30, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Percentage of Participants With Occurrence of Dysgeusia as Assessed by the Total Waterless Empirical Taste Test (WETT) Testing Score During the Prophylaxis Treatment Phase
Measured over: Up to 12 months
Percentage of Participants With Occurrence of Severe Dysgeusia During the Prophylaxis Treatment Phase
Measured over: Up to 12 months
Time to the First Onset of Severe Dysgeusia During the Prophylaxis Treatment Phase
Measured over: Up to 12 months
Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase
Measured over: End of Month 3
Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase
Measured over: End of Month 7
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06500884 · record last updated 2026-09-25 · checked 2026-11-09 15:47 UTC